Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy

BACKGROUND: Bringing antibodies from pre-clinical studies to human trials requires humanization, but this process may alter properties that are crucial for efficacy. Since pathological tau protein is primarily intraneuronal in Alzheimer's disease, the most efficacious antibodies should work bot...

Descripción completa

Detalles Bibliográficos
Autores principales: Congdon, Erin E., Chukwu, Jessica E., Shamir, Dov B., Deng, Jingjing, Ujla, Devyani, Sait, Hameetha B.R., Neubert, Thomas A., Kong, Xiang-Peng, Sigurdsson, Einar M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492224/
https://www.ncbi.nlm.nih.gov/pubmed/30910484
http://dx.doi.org/10.1016/j.ebiom.2019.03.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492224/
https://www.ncbi.nlm.nih.gov/pubmed/30910484
http://dx.doi.org/10.1016/j.ebiom.2019.03.033

Ejemplares similares